Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
2.

Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.

Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N.

Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23.

PMID:
25245812
3.

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

DiMarco JP, O'Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L.

Mult Scler Relat Disord. 2014 Sep;3(5):629-38. doi: 10.1016/j.msard.2014.05.005. Epub 2014 Jun 17.

PMID:
26265275
4.

Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).

Meissner A, Limmroth V.

Mult Scler Relat Disord. 2016 Jul;8:19-26. doi: 10.1016/j.msard.2016.04.002. Epub 2016 Apr 21. Review.

PMID:
27456870
5.

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7.

6.

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L; FIRST Study Investigators.

J Neurol. 2014 Feb;261(2):267-76. doi: 10.1007/s00415-013-7115-8. Epub 2013 Nov 13.

7.

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.

Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, Frider N, Alvarenga R.

Adv Ther. 2015 Jul;32(7):626-35. doi: 10.1007/s12325-015-0224-2. Epub 2015 Jul 14. Erratum in: Adv Ther. 2015 Jul;32(7):636.

8.

The effectiveness of fingolimod in a Portuguese real-world population.

Correia I, Batista S, Marques IB, Sousa M, Ferreira R, Nunes C, Macário MC, Sousa L.

Mult Scler Relat Disord. 2016 Mar;6:41-8. doi: 10.1016/j.msard.2016.01.003. Epub 2016 Jan 12.

PMID:
27063621
9.

Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.

Akbulak RÖ, Rosenkranz SC, Schaeffer BN, Pinnschmidt HO, Willems S, Heesen C, Hoffmann BA.

Mult Scler Relat Disord. 2018 Jan;19:44-49. doi: 10.1016/j.msard.2017.10.020. Epub 2017 Nov 2.

PMID:
29127856
10.

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators.

Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3.

PMID:
26265274
11.

Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.

Tichá V, Kodým R, Počíková Z, Kadlecová P.

Clin Drug Investig. 2017 Feb;37(2):175-186. doi: 10.1007/s40261-016-0471-2.

12.

A longitudinal real-life comparison study of natalizumab and fingolimod.

Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, De Rosa A, Brescia Morra V.

Acta Neurol Scand. 2017 Sep;136(3):217-222. doi: 10.1111/ane.12718. Epub 2016 Dec 15.

PMID:
27976804
14.

Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.

Bianco A, Patanella AK, Nociti V, Marti A, Frisullo G, Plantone D, De Fino C, Fetta A, Batocchi AP, Rossini PM, Mirabella M.

Eur Neurol. 2015;73(1-2):57-65. doi: 10.1159/000365968. Epub 2014 Nov 7.

PMID:
25402749
15.

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.

Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G.

PLoS One. 2017 Apr 28;12(4):e0176174. doi: 10.1371/journal.pone.0176174. eCollection 2017.

16.

Fingolimod effects on left ventricular function in multiple sclerosis.

Racca V, Di Rienzo M, Cavarretta R, Toccafondi A, Vaini E, Ferratini M, Rovaris M.

Mult Scler. 2016 Feb;22(2):201-11. doi: 10.1177/1352458515587753. Epub 2015 Jun 3.

PMID:
26041795
17.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
18.

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.

Ouspid E, Razazian N, Moghadasi AN, Moradian N, Afshari D, Bostani A, Sariaslani P, Ansarian A.

Neurosciences (Riyadh). 2018 Apr;23(2):129-134. doi: 10.17712/nsj.2018.2.20170434.

PMID:
29664454
19.

The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.

Datt J, Baldock L, Pull E, Webber B.

Mult Scler Relat Disord. 2016 Jan;5:40-6. doi: 10.1016/j.msard.2015.10.009. Epub 2015 Nov 3.

20.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D.

Mult Scler Relat Disord. 2015 May;4(3):273-80. doi: 10.1016/j.msard.2015.04.002. Epub 2015 Apr 13.

Supplemental Content

Support Center